Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Exelixis, Inc. - Common Stock
(NQ:
EXEL
)
62.83
+1.84 (+3.02%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Exelixis, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
Today 16:05 EDT
From
Exelixis, Inc.
Via
Business Wire
Exelixis (NASDAQ:EXEL): A Quality Stock With Durable Returns on Capital
↗
October 12, 2026
Via
Chartmill
Exelixis (NASDAQ:EXEL) Flashes Strong Technicals and Tight Breakout Setup
↗
October 05, 2026
Via
Chartmill
Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B
↗
September 17, 2026
Exelixis (NASDAQ:EXEL) President and CEO Michael Morrissey said the company is focused on expanding its oncology franchises through internal development, selective business development and potential...
Via
MarketBeat
Topics
Artificial Intelligence
Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle
↗
September 15, 2026
Exelixis (NASDAQ:EXEL) executives outlined plans to continue expanding the CABOMETYX franchise while preparing for a potential launch of zanzalintinib, or zanza, in colorectal cancer later this year....
Via
MarketBeat
Exelixis (NASDAQ:EXEL): A Value Stock Backed by Strong Fundamentals
↗
August 22, 2026
Via
Chartmill
Exelixis (NASDAQ:EXEL) Shows Strong Breakout Setup with Perfect Technical Rating
↗
August 06, 2026
Via
Chartmill
Exelixis (NASDAQ:EXEL) Posts Mixed Q2: EPS Beats, Revenue Misses, Guidance Lowered
↗
August 05, 2026
Via
Chartmill
Exelixis Inc. (NASDAQ:EXEL): A Decent Value Play in the Biotechnology Sector
↗
July 01, 2026
Via
Chartmill
Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer Franchises
↗
September 14, 2026
Exelixis (NASDAQ:EXEL) executives outlined a franchise-focused growth strategy centered on expanding CABOMETYX across renal cell carcinoma and neuroendocrine tumors while advancing zanzalintinib...
Via
MarketBeat
Topics
Artificial Intelligence
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
September 01, 2026
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
August 31, 2026
From
Exelixis, Inc.
Via
Business Wire
Exelixis Inc (NASDAQ:EXEL) Offers Decent Value with Strong Profitability and Financial Health
↗
June 09, 2026
Via
Chartmill
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law
August 16, 2026
From
Schall, Brown & Schwartz LLP
Via
Business Wire
Exelixis (EXEL) Q2 2026 Earnings Call Transcript
↗
August 12, 2026
Cabozantinib revenue grew 10%, while zanzalintinib advances toward FDA decision in December.
Via
The Motley Fool
Topics
Earnings
EXEL Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Exelixis (EXEL)
August 12, 2026
From
Levi & Korsinsky, LLP
Via
Business Wire
Exelixis Q2 Earnings Call Highlights
↗
August 05, 2026
Exelixis (NASDAQ:EXEL) reported second-quarter 2026 revenue of approximately $629 million, including $573 million in cabozantinib franchise net product revenue, as the company prepared for a potential...
Via
MarketBeat
Topics
Earnings
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
August 05, 2026
From
Exelixis, Inc.
Via
Business Wire
These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside Ahead
↗
July 24, 2026
They are riding strong tailwinds that could lift them higher.
Via
The Motley Fool
Topics
Economy
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
July 22, 2026
From
Exelixis, Inc.
Via
Business Wire
3 Under-the-Radar Stocks to Buy and Hold
↗
July 10, 2026
Sometimes, little-known stocks are worth buying.
Via
The Motley Fool
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
June 22, 2026
From
Exelixis, Inc.
Via
Business Wire
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year
↗
May 30, 2026
Ultragenyx develops therapies for rare genetic diseases, with a portfolio spanning approved biologics and a pipeline of gene therapies.
Via
The Motley Fool
Topics
Regulatory Compliance
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
May 30, 2026
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June
May 27, 2026
From
Exelixis, Inc.
Via
Business Wire
Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near
↗
May 23, 2026
Exelixis (NASDAQ:EXEL) remains focused on expanding its CABO franchise while preparing for potential launches and data readouts tied to zanzalintinib, Andrew Peters, the company’s senior vice president...
Via
MarketBeat
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
May 21, 2026
From
Exelixis, Inc.
Via
Business Wire
GlobeFlex Exits NCR Atleos After Brink’s Buyout Deal
↗
May 20, 2026
NCR Atleos delivers self-service banking technology and managed services to financial institutions and enterprise clients worldwide.
Via
The Motley Fool
Topics
Regulatory Compliance
Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer
May 19, 2026
From
Exelixis, Inc.
Via
Business Wire
Prediction: This Stock Could Double By 2031
↗
May 15, 2026
It's not the most prominent company in its industry, but it is definitely worth a second look.
Via
The Motley Fool
Topics
Intellectual Property
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
